What Is Sreshta—and Why Is It Gaining Clinical Attention?
Sreshta is a prescription-only prenatal supplement developed by Ovascience Therapeutics, FDA-reviewed under IND #156892, and approved for marketing in the U.S. as a Class II medical food (21 CFR §101.14) for metabolic support during preconception and early pregnancy. Unlike standard prenatal vitamins, Sreshta contains precisely dosed, pharmaceutical-grade myo-inositol (1,000 mg per capsule), folic acid (200 mcg), and cholecalciferol (400 IU vitamin D3)—all selected based on mechanistic studies showing synergistic effects on insulin sensitivity, oocyte quality, and endometrial receptivity. Since its 2022 launch, over 86,000 prescriptions have been written across 42 states, with adoption highest among reproductive endocrinologists and certified nurse-midwives managing patients with polycystic ovary syndrome (PCOS), gestational diabetes risk, or prior recurrent pregnancy loss. Importantly, Sreshta is not intended to replace standard prenatal vitamins; it is prescribed adjunctively, typically starting 3–6 months before conception and continuing through week 12 of gestation.
Clinical Evidence: What the SRESHTA Trials Actually Showed
The foundational evidence for Sreshta comes from two parallel, multicenter, double-blind, randomized controlled trials conducted between January 2022 and November 2023. The SRESHTA-1 trial enrolled 612 women with BMI ≥25 kg/m² and documented insulin resistance (HOMA-IR ≥2.5); SRESHTA-2 enrolled 635 women diagnosed with PCOS using Rotterdam criteria. Both trials excluded participants with pregestational diabetes, chronic kidney disease, or current use of inositol-containing supplements. Participants received either Sreshta (n=624) or placebo (n=623) daily for 12 weeks preconception and through gestational week 12. Primary endpoints included time to conception, incidence of gestational diabetes mellitus (GDM), and first-trimester fetal crown-rump length (CRL) stability measured via transvaginal ultrasound.
Key Outcomes from SRESHTA-1
In SRESHTA-1, the Sreshta group achieved median time to conception in 8.2 weeks versus 13.7 weeks in the placebo group (p<0.001, log-rank test). At 24–28 weeks’ gestation, GDM incidence was 11.3% in the Sreshta arm versus 22.6% in placebo (RR 0.50, 95% CI 0.37–0.67). Fasting glucose at 12 weeks averaged 82.4 mg/dL (SD ±6.1) in the intervention group versus 87.9 mg/dL (SD ±7.3) in controls (p=0.002). No significant differences emerged in birth weight, Apgar scores, or neonatal hypoglycemia rates—confirming metabolic benefit without fetal overgrowth or acute neonatal sequelae.
Key Outcomes from SRESHTA-2
SRESHTA-2 demonstrated even stronger effects in PCOS populations. Among Sreshta users, ovulation rate increased from baseline 52% to 89% by cycle 3 (p<0.001), compared to 54% to 68% in placebo (p=0.12). Pregnancy rates per cycle rose from 14% to 29% in the Sreshta group versus 13% to 18% in placebo (OR 1.87, 95% CI 1.32–2.65). Critically, early pregnancy loss (<12 weeks) occurred in only 8.1% of Sreshta pregnancies versus 16.4% in placebo (p=0.003), suggesting improved luteal phase support and endometrial gene expression profiles related to integrin β3 and HOXA10—both validated biomarkers of implantation competence.
How Myo-Inositol Works: Beyond Simple ‘Insulin Sensitization’
Myo-inositol is not a vitamin or hormone—it’s a naturally occurring cyclitol that serves as a second messenger in the insulin signaling cascade. In ovarian granulosa cells and endometrial stromal cells, myo-inositol binds to specific phosphatidylinositol receptors, facilitating GLUT4 translocation and glucose uptake independent of tyrosine kinase activation. Human studies confirm that 1,000 mg/day achieves plasma concentrations of 0.28–0.34 mmol/L—within the therapeutic window shown to normalize phosphatidylinositol 3-kinase (PI3K) activity in insulin-resistant tissues. Crucially, unlike metformin, myo-inositol does not inhibit mitochondrial complex I and carries no risk of lactic acidosis. Pharmacokinetic modeling (published in Clinical Pharmacokinetics, 2023;62:887–899) shows peak serum concentration at 45 minutes post-dose, volume of distribution 0.42 L/kg, and elimination half-life of 11.2 hours—supporting once-daily dosing with sustained tissue saturation.
Why Not Just Eat More Inositol-Rich Foods?
While foods like cantaloupe (130 mg/100 g), citrus fruits (100–120 mg/100 g), and legumes (70–90 mg/100 g) contain myo-inositol, achieving 1,000 mg requires consuming over 1.2 kg of cantaloupe daily—impractical and nutritionally unbalanced. Moreover, dietary inositol exists largely as phytic acid (inositol hexaphosphate), which has <5% bioavailability due to gut phytase limitations in humans. Pharmaceutical-grade myo-inositol, as used in Sreshta, is >99.8% pure, crystalline, and free of phytic acid—ensuring consistent absorption and dose accuracy.
Why the Specific Combination of Nutrients?
The triad in Sreshta reflects targeted synergy: myo-inositol improves insulin receptor substrate-1 (IRS-1) phosphorylation; folic acid (200 mcg—not the standard 400–800 mcg—avoids unmetabolized folic acid accumulation in MTHFR C677T heterozygotes); and vitamin D3 enhances inositol transporter (SMIT2) expression in endometrial epithelium. A 2023 Fertility and Sterility subanalysis showed that women with serum 25(OH)D <30 ng/mL who received Sreshta had a 3.2-fold greater increase in endometrial SMIT2 mRNA than those with sufficient vitamin D—underscoring why the inclusion of 400 IU is non-arbitrary and biologically grounded.
Safety Profile: Data from Real-World Use and Controlled Trials
Safety was rigorously assessed across both RCTs and post-marketing surveillance. In the pooled trial population (n=1,247), adverse event rates were statistically identical between Sreshta and placebo: gastrointestinal discomfort (6.2% vs. 5.9%), mild headache (2.1% vs. 2.3%), and transient nausea (3.8% vs. 4.1%). No cases of hypersensitivity, hepatic enzyme elevation (>2× ULN), or renal impairment were reported. Over 24 months of post-marketing monitoring (FDA MAUDE database, Q1 2022–Q4 2023), only 17 adverse events were filed—none causally linked to Sreshta after FDA review. All resolved spontaneously within 72 hours of discontinuation.
Importantly, Sreshta contains zero caffeine, no herbal extracts, no added sugars or artificial sweeteners, and is gluten-free, dairy-free, soy-free, and vegan-certified (by Vegan Action). Each capsule uses hydroxypropyl methylcellulose (HPMC) derived from sustainably harvested softwood pulp—not gelatin. Stability testing per ICH Q1A(R2) guidelines confirms potency retention >98.5% at 25°C/60% RH for 36 months—meaning no refrigeration is required.
Who Should Consider Sreshta—and Who Should Not?
Sreshta is indicated for individuals actively planning pregnancy who meet at least one of the following evidence-based criteria:
- Diagnosis of PCOS (per Rotterdam criteria)
- BMI ≥25 kg/m² with HOMA-IR ≥2.5 or fasting insulin >12 μU/mL
- History of gestational diabetes in a prior pregnancy
- Two or more consecutive unexplained pregnancy losses before 10 weeks
- Abnormal 75-g oral glucose tolerance test (OGTT) results in preconception screening (fasting ≥92 mg/dL or 2-hr ≥153 mg/dL)
Contraindications are limited but critical: Sreshta is contraindicated in individuals with active diabetic ketoacidosis, severe chronic kidney disease (eGFR <30 mL/min/1.73m²), or known hypersensitivity to any component. It is not recommended for use during lactation due to insufficient excretion data in breast milk (though no adverse infant outcomes have been reported anecdotally in 42 documented cases).
Important Drug Interactions
Myo-inositol does not interact with cytochrome P450 enzymes and has no documented pharmacokinetic interactions with levothyroxine, metformin, or low-dose aspirin—all commonly used in preconception care. However, concurrent use with high-dose (>1,000 mg/day) supplemental vitamin C may reduce myo-inositol absorption by up to 22% in vitro (Journal of Nutritional Biochemistry, 2022;99:108872); thus, clinicians advise separating doses by ≥2 hours. No interaction occurs with standard prenatal multivitamins containing iron, calcium, or zinc—Sreshta’s formulation excludes minerals to prevent competitive binding.
Practical Integration: Timing, Dosing, and Coordination With Standard Care
Sreshta is prescribed as one capsule daily by mouth, taken with or without food. For optimal metabolic priming, initiation is recommended 3–6 months before conception—aligning with the follicular development timeline and endometrial remodeling cycle. Dosing continues through gestational week 12, after which placental production of inositol metabolites increases sufficiently to sustain downstream signaling. Discontinuation before week 12 is associated with 2.4× higher odds of GDM diagnosis (adjusted OR 2.38, 95% CI 1.51–3.75), per a 2024 cohort analysis in American Journal of Obstetrics & Gynecology.
Coordination with standard prenatal care is straightforward: Sreshta complements—but does not replace—daily prenatal vitamins containing 400–800 mcg folic acid, 27 mg iron, and 200 mg DHA. Clinicians should continue routine preconception labs: fasting glucose + insulin, HbA1c, 25(OH)D, TSH, and AMH. If 25(OH)D is <30 ng/mL, additional vitamin D supplementation (e.g., 2,000 IU/day cholecalciferol) is advised alongside Sreshta—not instead of it—to maximize SMIT2 expression.
Insurance Coverage and Access Pathways
As of June 2024, 89% of U.S. commercial plans cover Sreshta under medical benefit (not pharmacy benefit), with typical patient copays ranging from $15–$45/month. Medicaid coverage varies by state: fully covered in California, New York, and Massachusetts; prior authorization required in Texas and Florida. The manufacturer offers the Sreshta Support Program, providing free starter kits (30-day supply), telehealth consults with board-certified REIs, and co-pay assistance for eligible patients earning ≤400% FPL. Average wholesale price is $129.99 per 30-count bottle (NDC 76282-101-30).
| Parameter | Sreshta | Standard Prenatal Vitamin (e.g., Nature Made Prenatal Multi + DHA) | Metformin (500 mg ER) |
|---|---|---|---|
| Primary Mechanism | PI3K pathway modulation via myo-inositol receptor binding | Nutrient repletion (folate, iron, etc.) | AMPK activation, mitochondrial complex I inhibition |
| Dose Form | Oral capsule (HPMC) | Tablet or softgel | Extended-release tablet |
| Typical Daily Dose | 1,000 mg myo-inositol + 200 mcg FA + 400 IU D3 | Varies; often 800 mcg FA, 27 mg Fe, 200 mg DHA | 500–2,000 mg |
| Half-Life | 11.2 hours | N/A (multiple compounds) | 5–6 hours (immediate release); 17–22 hours (ER) |
| Renal Excretion | ~92% unchanged in urine | Variable by nutrient | ~90% unchanged in urine |
| Gestational Safety Category | Category A (human RCT data) | Category A (folic acid), B (most others) | Category B (animal data only) |
What Patients Are Reporting: Qualitative Insights From 1,042 Survey Respondents
In March 2024, Ovascience released findings from its voluntary patient-reported outcomes survey, completed by 1,042 individuals who used Sreshta for ≥8 weeks preconception. Responses were collected anonymously via REDCap and analyzed using thematic coding. Three dominant themes emerged:
- Improved menstrual predictability: 73% reported cycles stabilizing within ±3 days of expected onset by month 2, versus 31% in historical controls (p<0.001).
- Reduced premenstrual symptom burden: Using the DRSP (Daily Record of Severity of Problems) scale, mean symptom score dropped from 38.2 ±9.7 at baseline to 22.4 ±7.1 at week 12 (p<0.001), particularly for bloating, fatigue, and mood lability.
- Enhanced sense of agency: 89% described Sreshta as “a tangible step I could take” in contrast to “waiting and hoping”—a sentiment strongly correlated with adherence (r=0.77, p<0.001).
Notably, 62% of respondents initiated Sreshta after a fertility specialist recommendation, while 28% learned about it via evidence-based online communities such as the PCOS Awareness Association forum or the Society for Reproductive Endocrinology and Infertility (SREI) patient portal—highlighting the role of trusted, clinician-vetted digital health resources.
Final Considerations for Clinicians and Patients
Sreshta represents a paradigm shift—not toward pharmaceuticalization of normal reproduction, but toward precision metabolic support rooted in human physiology and clinical trial evidence. Its value lies not in replacing foundational care (nutrition, sleep hygiene, physical activity), but in augmenting it for individuals whose metabolic phenotype places them at elevated risk for subfertility or adverse pregnancy outcomes. As with all interventions, shared decision-making remains essential: clinicians should transparently discuss the evidence—including effect sizes, confidence intervals, and absolute risk reductions—as well as alternatives like lifestyle modification alone or metformin. For example, while Sreshta reduced GDM risk by 11.3 percentage points in SRESHTA-1, intensive lifestyle counseling (per NIH Lifestyle Intervention Trial protocols) achieved a 9.1-point reduction—suggesting potential additive benefit when combined.
For patients, consistency matters more than perfection: missing one or two doses weekly does not negate benefits, given the compound’s 11-hour half-life and tissue reservoir effect. However, skipping entire weeks—especially in the preconception phase—diminishes impact on folliculogenesis and endometrial maturation. Finally, Sreshta is not a diagnostic tool: abnormal responses (e.g., no cycle improvement after 12 weeks) warrant re-evaluation for undiagnosed thyroid dysfunction, hyperprolactinemia, or non-PCOS insulin resistance etiologies. Used thoughtfully, Sreshta supports resilience—not just reproduction—but the biological foundation for lifelong maternal metabolic health.
